RUBY YUN-JU HUANGKUAN-JU HUANGChen, Ko-ChenKo-ChenChenHsiao, Sheng-MouSheng-MouHsiaoTan, Tuan ZeaTuan ZeaTanCHIN-JUI WUHsu, ChingChingHsuWEN-CHUN CHANGPan, Chen-YuChen-YuPanBOR-CHING SHEULIN-HUNG WEI2023-03-132023-03-132023-05-150020-7136https://scholars.lib.ntu.edu.tw/handle/123456789/629212Ovarian clear cell carcinoma (OCCC) is a distinct histotype of ovarian cancer, which usually presages a worse prognosis upon recurrence. Identifying patients at risk for relapse is an unmet need to improve outcomes. A retrospective cohort analysis of 195 early-stage OCCC patients diagnosed between January 2011 and December 2019 at National Taiwan University Hospital was conducted to identify prognostic factors for recurrence, progression-free survival (PFS) and overall survival (OS). Molecular profiling of tumors was performed in a case-controlled cohort matched for adjuvant therapy for biomarker discovery. Multivariate Cox proportional hazard model revealed that paclitaxel-based chemotherapy was associated with better PFS than nonpaclitaxel chemotherapy (HR = 0.19, P = .006). The addition of bevacizumab was associated with better PFS, compared to no bevacizumab (HR = 0.09, P = .02). Neither showed significant improvement in OS. Recurrence is associated with an Immune-Hot tumor feature (P = .03), the CTLA-4-high subtype (P = .01) and increased infiltration of immune cells in general. The Immune-Hot feature (HR = 3.39, P = .005) and the CTLA-4-high subtype (HR = 2.13, P = .059) were associated with worse PFS. Immune-Hot tumor features could prognosticate recurrence in early-stage OCCC.enbevacizumab; immune profiling; ovarian clear cell carcinoma[SDGs]SDG3[SDGs]SDG5journal article10.1002/ijc.34428366292832-s2.0-85147304252WOS:000923400800001https://api.elsevier.com/content/abstract/scopus_id/85147304252